Shares of Avrobio Inc (NASDAQ:AVRO) have received an average rating of “Buy” from the nine analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $34.25.
Several analysts have issued reports on the stock. Leerink Swann decreased their price target on shares of Avrobio from $27.00 to $19.00 and set a “market perform” rating on the stock in a research report on Thursday, January 17th. Zacks Investment Research lowered shares of Avrobio from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th. Finally, HC Wainwright restated a “buy” rating on shares of Avrobio in a research report on Tuesday, January 15th.
Large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new position in shares of Avrobio during the 3rd quarter worth about $48,000. Great West Life Assurance Co. Can bought a new stake in shares of Avrobio during the 4th quarter worth $34,000. American International Group Inc. bought a new stake in shares of Avrobio during the 3rd quarter worth $210,000. Rhumbline Advisers bought a new stake in shares of Avrobio during the 3rd quarter worth $235,000. Finally, Man Group plc bought a new stake in shares of Avrobio during the 3rd quarter worth $329,000. 69.47% of the stock is owned by institutional investors.
Avrobio Company Profile
AVROBIO, Inc, a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease.
Recommended Story: What is the yield curve?
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.